Is Pretreatment with Beta-Blockers Beneficial in Patients with Acute Coronary Syndrome? by Cuculi, F. et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Research 
 Cardiology 2010;115:91–97 
 DOI: 10.1159/000256384 
 Is Pretreatment with Beta-Blockers 
Beneficial in Patients with Acute Coronary 
Syndrome? 
 F. Cuculi a    D. Radovanovic b    G. Pedrazzini c    M. Regli d    P. Urban e    J.C. Stauffer f    
P. Erne g    on behalf of the AMIS Plus Investigators 
 a  Department of Cardiology, University Hospital Bern,  Bern ,  b  Institute of Social and Preventive Medicine,
University of Zurich,  Zurich ,  c  Division of Cardiology, Cardiocentro Ticino,  Lugano ,  d  Department of Internal Medicine, 
Spital Thun-Simmenthal,  Thun ,  e  Cardiovascular Department, La Tour Hospital,  Geneva ,  f  Department of Cardiology, 
Centre Hospitalier Universitaire Vaudois,  Lausanne , and  g  Department of Cardiology, Luzerner Kantonsspital,
 Luzern , Switzerland 
the multivariate analysis, odds ratio for major adverse car-
diac events was 0.59 (CI 0.47–0.74) for group A and 0.66 (CI 
0.55–0.83) for group B, while group C was taken as a refer-
ence.  Conclusions:   -Blocker therapy is beneficial in ACS 
and they should be started in those who are not pretreated 
and continued in stable patients who had been on chronic 
  -blocker therapy before. 
 
Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 While the role of   -receptor-blocking agents (  -block-
ers) has been challenged recently as a first choice in the 
treatment of systemic hypertension  [1, 2] ,   -blockers re-
main recommended medications for patients with chron-
ic coronary artery disease  [3] , especially those after acute 
myocardial infarction (AMI)  [4–6] .
 In 1999, Freemantle et al.  [7] assessed the role of   -
blockers in a large meta-analysis of 54,234 patients with 
myocardial infarction. They found that   -blockers are ef-
fective in the long-term secondary prevention after myo-
cardial infarction, reporting a 23% reduction in the odds 
of death in long-term trials (95% CI 15–31%). Similar 
long-term results were reported by the   -blocker pooling 
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 Abstract 
 Objectives: The role of   -blockers in the treatment of hyper-
tension is discussed controversially and the data showing a 
clear benefit in acute coronary syndromes (ACS) were ob-
tained in the thrombolysis era. The goal of this study was to 
analyze the role of pretreatment with   -blockers in patients 
with ACS.  Methods: Using data from the Acute Myocardial 
Infarction in Switzerland (AMIS Plus) registry, we analyzed 
outcomes of patients with   -blocker pretreatment in whom 
they were continued during hospitalization (group A), those 
without   -blocker pretreatment but with administration af-
ter admission (group B) and those who never received them 
(group C). Major adverse cardiac events defined as com-
posed endpoint of re-infarction and stroke (during hospital-
ization) and/or in-hospital death were compared between 
the groups.  Results: A total of 24,709 patients were included 
in the study (6,234 in group A, 12,344 in group B, 6,131 in 
group C). Patients of group B were younger compared to pa-
tients of group A and C (62.5, 67.6 and 68.4, respectively). In 
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research group  [8] and the Cooperative Cardiovascular 
Project  [9] .
 The impact of   -blocker treatment on early outcomes 
after myocardial infarction has been discussed contro-
versially. Freemantle et al.  [7] did not observe a positive 
short-term effect of   -blockers administered immediate-
ly after AMI (4% reduction in the odds of death; –8 to 
15%).
 Also, the role of early intravenous   -blocker therapy 
has been disputed. While early studies performed in pa-
tients without reperfusion therapy demonstrated a mor-
tality benefit  [10, 11] , studies in the thrombolysis era 
showed no survival benefit  [12, 13] or even an increased 
mortality  [14] . However, in the study by Pfisterer et al. 
 [14] , atenolol was used, a   -blocker which has been wide-
ly criticized lately, especially in hypertension trials.
 Administration of intravenous   -blockers before pri-
mary percutaneous coronary intervention (PCI) was 
found to enhance myocardial recovery and reduce 30-day 
mortality in patients with AMI undergoing primary PCI 
 [15] . A pooled analysis of 3 prospective trials showed that 
pretreatment with   -blockers has an independent benefi-
cial effect on short-term clinical outcomes in patients un-
dergoing primary angioplasty for AMI  [16] . In the most 
recent study, which analyzed the role of   -blockers in the 
treatment of AMI, 45,000 patients were randomized to 
intravenous (continued with oral) metoprolol therapy or 
placebo. The rate of death, re-infarction or cardiac arrest 
was similar between both groups in this study  [17] .
 One of the mechanisms how   -blockers could poten-
tially improve prognosis in ACS is heart-rate reduction 
 [18, 19] . However, the concept of sole heart-rate reduction 
is discussed controversially after the publication of the 
BEAUTIFUL trial, which failed to reduce cardiovascular 
mortality in stable patients with coronary artery disease 
(CAD) and reduced left ventricular function, although 
reducing the rates of fatal and nonfatal myocardial in-
farction in these patients  [20] .
 Since the short-term effect of early administration of 
  -blockers in patients with unstable angina or AMI re-
mains controversial and little is known about the early 
outcome of AMI patients already treated with   -block-
ers, there is need for further investigation.
 Using data from the Acute Myocardial Infarction in 
Switzerland (AMIS Plus) registry, a large national regis-
try of ACS, we have analyzed the effect of previous   -
blocker therapy on the outcome of patients with ACS. 
Our hypothesis was that in patients with ACS, previous 
  -blocker therapy does not offer additional benefit to a 
  -blocker therapy started after admission.
 Methods 
 The AMIS Plus Registry 
 The AMIS Plus project is a nationwide prospective registry of 
patients admitted with ACS to hospitals in Switzerland. The reg-
istry began in 1997, and patient recruitment has been ongoing 
since. Participating centers, ranging from community institu-
tions to large tertiary facilities, provide blinded data for each pa-
tient through a standardized Internet- or paper-based question-
naire. The details of the AMIS Plus Project have been published 
elsewhere  [21–24] .
 Patients 
 The AMIS Plus registry included all patients with ACS: AMI 
defined by characteristic symptoms and/or ECG changes and car-
diac marker elevation (either total creatine kinase or creatine ki-
nase MB fraction at least twice the upper limit of normal or tro-
ponin I or T above individual hospital cutoff for myocardial
infarction), ACS with minimal necrosis (symptoms or ECG 
changes compatible with ACS and cardiac marker level lower than 
cutoff for myocardial infarction) and unstable angina (symptoms 
or ECG changes compatible with ACS and normal cardiac mark-
ers). Patients were also categorized as having ST-segment eleva-
tion ACS (STEMI) or non-ST-segment elevation ACS (NSTEMI) 
based on initial ECG findings. Classification of STEMI included 
evidence of ACS as above and ST-segment elevation and/or new 
left bundle branch block on the initial ECG. NSTEMI included 
patients with ischemic symptoms, ST-segment depression or T-
wave abnormalities in the absence of ST-elevation on the initial 
ECG. Valid data since 1997 on pretreatment and early treatment 
with   -blockers were available and those data were analyzed. 
Baseline characteristics and outcomes are compared between pa-
tients on chronic   -blocker therapy (group A), patients without 
  -blocker pretreatment and in whom   -blocker therapy was 
started after admission (group B), and patients without   -blocker 
pretreatment who were not started on a   -blocker when admitted 
(group C). Major adverse cardiac event (MACE) was defined as a 
composed endpoint of re-infarction, stroke and/or in-hospital 
death. Comorbidities of the patients were assessed using the 
Charlson index  [25] . In March 2005, the AMIS Plus questionnaire 
was revised and more angiographic parameters were added (for 
example: vessel treated, left ventricular ejection fraction, throm-
bolysis in myocardial infarction flow at the end of PCI).
 Statistical Analyses 
 Data are presented as percentages of valid cases for discrete 
variables and as means  8 SD and/or median for continuous vari-
ables. Differences in baseline characteristics were compared us-
ing t test and   2 tests. A p value of  ! 0.05 was considered signifi-
cant. User-defined missing values are treated as missing. Statis-
tics for each table are based on all cases with valid data in the 
specified ranges for all variables in each table. Odds ratios (OR) 
with 95% CI for OR of in-hospital mortality were calculated using 
logistic regression models. The following factors were included in 
the multivariate analysis:   -blocker treatment, age, gender, his-
tory of coronary artery disease, hypertension, diabetes, dyslipid-
emia, smoking, overweight, ST-segment elevation, Charlson 
score, Killip class and use of PCI. SPSS software (version 15.0; 
SPSS Inc., Chicago, Ill., USA) was used for all statistical analy-
ses.
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 Results 
 From 26,964 registered patients between January 1st 
1997 to December 31st 2007, 24,709 patients (91.6%) had 
valid data on previous and/or early treatment with   -
blockers. For 2,255 patients (8.4%), treatment with   -
blockers was unknown or data were missing.
 7,684 patients (29.4%) had previous   -blocker thera-
py, and in 6,234 of these patients this therapy was con-
tinued after admission (group A; in 1,450 patients   -
blockers were stopped after admission); in 12,344 (47.2%) 
patients   -blocker therapy was started at admission 
(group B); 6,131 (23.4%) patients never received   -block-
er therapy (group C). Baseline characteristics of the 
study population are shown in  table 1 . The mean age of 
all patients was 65.6 years ( 8 13.2) and 72.3% of them 
were males. Patients of group A were significantly older 
than patients of group B (67.6 vs. 62.5 years, p  ! 0.001) 
but had a similar age as patients of group C (68.4 
years).
 Patients of group A had a higher proportion of diabe-
tes (24.3 vs. 15.8% in group B and 22% in group C, p  ! 
0.001) and a higher proportion of arterial hypertension 
(79.9 vs. 45.2% in group B and 50.4% in group C).
 The rate of STEMI was higher in patients of groups B 
and C (62.4 and 62.8%) compared to patients of group A 
(47.6%, p  ! 0.001).
 The anti-thrombotic therapy is shown in the bottom 
part of  table 1 . Patients from group C received less aspirin 
and less clopidogrel than those of group A and B.
 In  table 2 , the Killip classifications of the patients are 
summarized. Patients of group B were more likely to be 
in Killip class I (84.5%) compared to patients of group A 
(77%) and patients of group C (66.1%).
 Table 3 summarizes the reperfusion therapies for 
ACS patients in the AMIS Plus population. A reperfu-
sion therapy (thrombolysis or primary PCI) was per-
formed in 45.8% of patients of group A, 55.9% of pa-
tients of group B and 48% of patients of group C. Pri-
mary PCI was the predominant reperfusion therapy in 
all groups.
 Median door-to-balloon times for PCI-treated pa-
tients were 193 min for group A, 117 min for group B and 
109 min for group C (p  ! 0.001). Median door-to-needle 
time for thrombolysis-treated patients was 35 min in 
group A and 30 min in group B and C (p = 0.032).
 In  table 4 , the complications and outcome of ACS pa-
tients during hospitalization are demonstrated. Patients 
of group B had similar rates or cardiogenic shock (3.8 vs. 
Table 1. Baseline characteristics of the study population 
All ACS patients
(N = 26,964)
ACS patients with valid data on BB (N = 26,159) p between 
groupsgroup A
previous and continued
BB (n = 6,234)
group B
BB on admission
(n = 12,344)
group C
never BB
(n = 6,131)
Mean age, years1 65.6 (13.2) 67.6 (12.0) 62.5 (13.1) 68.4 (13.6) <0.001
Male patients, % 72.3 70.9 75.5 69.0 <0.001
STEMI, n/N 15,807/26,881 (58.8) 2,961/6,216 (47.6) 7,696/12,326 (62.4) 3,835/6,108 (62.8) <0.001
CAD, n/N 8,692/22,226 (39.1) 3,520/5,575 (63.1) 2,534/10,025 (25.3) 1,676/4,793 (35.0) <0.001
Diabetes, n/N 5,207/26,045 (20.0) 1,483/6,094 (24.3) 1,893/12,002 (15.8) 1,302/5,911 (22.0) <0.001
Hypertension, n/N 14,717/25,794 (57.1) 4,877/6,105 (79.9) 5,350/11,833 (45.2) 2,927/5,809 (50.4) <0.001
Dyslipidemia, n/N 13,800/24,136 (57.2) 4,024/5,764 (69.8) 6,109/11,272 (54.2) 2,516/5,233 (48.1) <0.001
Smoking, n/N 9,616/25,356 (37.9) 1,658/5,891 (28.1) 5,247/11,916 (44.0) 2,093/5,622 (37.2) <0.001
Obesity, n/N 4,110/21,470 (19.1) 1,142/5,204 (21.9) 1,847/10,155 (18.2) 795/4,464 (17.8) <0.001
Antithrombotic therapy aspirin 5,913/6,229 (94.9) 12,024/12,333 (97.5) 5,482/6,122 (89.5) <0.001
clopidogrel 3,353/6,206 (54.0) 6,632/12,298 (53.9) 2,591/6,116 (42.4) <0.001
UFH 3,989/6,197 (64.4) 9,080/12,305 (73.8) 4,288/6,117 (70.1) <0.001
LMWH 1,941/5,333 (36.4) 3,578/9,755 (36.7) 1,264/4,577 (27.6) <0.001
GP IIb/IIIa 1,544/5,347 (28.9) 3,716/9,779 (38.0) 1,341/4,579 (29.3) <0.001
Numbers in parentheses are percentages, unless indicated otherwise. BB = -Receptor-blocking agents; CAD = coronary artery 
disease.
1 Figures in parentheses are SD.
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3.7% in group A) but lower rates than group C (13.8%,
p  ! 0.001). Re-infarction rates were 2.5% in group A,
1.9% in group B and 2.8% in group C.
 Unadjusted MACE rates were similar in patients with 
  -blocker therapy on admission (group B) compared to 
those with previous   -blocker therapy (group A) (5.1 vs. 
6.5%) but lower than those who never received   -blockers 
(group C, 15.5%).
 The unadjusted in-hospital mortality was 4.1% for 
group A, 3.2% for group B and 13.2% for group C.
 In  table 5 , a multivariate logistic regression for major 
adverse cardiac events is shown. Factors increasing the 
MACE OR are age, STEMI, a higher Killip Class, the his-
tory of CAD, diabetes and an increasing Charlson score. 
The OR for   -blocker therapy on admission (group B) 
was 0.66, while the OR for previous   -blocker therapy 
(group A) was 0.59.
Table 2. Killip classification
All ACS
patients
(N = 26,964)
ACS patients with valid data on BB (N = 26,159) p between
groupsgroup A: previous and continued BB
(n = 6,234)
group B: BB on admission
(n = 12,344)
group C: never BB
(n = 6,131)
Class I 76.9 77.3 84.5 66.1 <0.001
Class II 16.1 17.7 12.7 20.2 <0.001
Class III 4.5 4.0 2.0 8.5 <0.001
Class IV 2.5 1.0 0.8 5.2 <0.001
BB = -Receptor blocking agents. Between BB groups p < 0.001.
Table 3. Reperfusion therapy
All ACS 
patients
(N = 26,964)
ACS patients with valid data on BB (N = 26,159) p between 
groupsgroup A: previous and continued BB
(n = 6,234)
group B: BB on admission 
(n = 12,344)
group C: never BB
(n = 6,131)
No reperfusion, % 48.8 54.2 44.1 52.0 <0.001
Thrombolysis, % 10.2 6.7 12.7 9.7 <0.001
Primary PCI, % 41.0 39.1 43.2 38.3 <0.001
BB = -Receptor-blocking agents. Between BB groups p < 0.001.
Table 4. Complications and outcome of ACS patients in the AMIS Plus Registry
All ACS patients
(N = 26,964)
ACS patients with valid data on BB
(N = 26,159)
p
previous and continued BB
(n = 6,234)
BB on admission
(n = 12,344)
never BB
(n = 6,131)
Cardiogenic shock, n/N 1,909/26,603 (7.2) 227/6,161 (3.7) 469/12,200 (3.8) 832/6,046 (13.8) <0.001
Re-infarction, n/N 637/26,540 (2.4) 156/6,152 (2.5) 236/12,185 (1.9) 170/6,025 (2.8) <0.001
Cerebrovascular event, n/N 279/26,349 (1.1) 56/6,111 (0.9) 80/12,071 (0.7) 90/5,995 (1.5) <0.001
MACE, n/N 2,430/26,396 (9.2) 399/6,113 (6.5) 613/12,078 (5.1) 930/6,015 (15.5) <0.001
In-hospital mortality, n/N 1,890/26,964 (7.0) 256/6,234 (4.1) 394/12,344 (3.2) 808/6,131 (13.2) <0.001
Numbers in parentheses are percentages. BB = -Receptor-blocking agents.
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 Discussion 
 We analyzed a large population of patients with ACS 
who are prospectively registered in the AMIS Plus data-
base. The majority of the patients (71%) with ACS in Swit-
zerland receive   -blocker therapy (either pretreated and 
continued or started during hospitalization). The pro-
portion of   -blockers’ use in our population is slightly 
lower compared to the proportion reported in the Wor-
cester Heart Attack Study where in 1999, 82% of the pa-
tients received this therapy after AMI  [26] .
 The unadjusted MACE and in-hospital mortality rate 
were slightly better in patients with   -blocker therapy 
started after admission, compared to those who had a 
chronic   -blocker therapy or those who never received a 
  -blocker ( table 4 ). However, it’s important to recognize 
the fact that there were significant differences between 
the different   -blocker groups ( table 1 ). One of the most 
important factors was age. Patients with previous   -
blocker therapy and those who never received a   -block-
er were more than 5 years older than patients with   -
blocker therapy started after admission. It is well known 
that age increases the risk for adverse outcomes after non-
invasive and invasive therapies for AMI  [27, 28] . One of 
the reasons for this phenomenon is probably the lower 
use of guideline-recommended medical and interven-
tional therapies in elderly patients  [23] . Increased percu-
taneous coronary intervention rates have been associated 
with decreased mortality among patients with ACS who 
present with cardiogenic shock or STEMI in Switzerland 
 [29, 30] .
 Further factors possibly explaining higher MACE 
rates are the higher prevalence of diabetes and coronary 
artery disease in patients pretreated with   -blocking 
agents than those without a   -blocker therapy. A factor 
favoring a worse outcome in patients with   -blocker 
therapy after admission is the higher proportion of STE-
MI in this group (62.4 vs. 47.6% in patients with previous 
  -blocker therapy).
 Since the baseline characteristics of the groups were 
different, we performed a multivariate logistic regression 
analysis, which included the Charlson comorbidity score 
and is shown in  table 5 . According to this analysis, both 
previous   -blocker therapy and   -blocker therapy after 
admission are beneficial in patients with ACS. This mul-
tivariate analysis favors pretreatment with   -blockers in-
dicating a 41% reduction of OR with a 95% CI of 0.47–
0.74.
 What could be the impact of these results when deal-
ing with patients who present with ACS? Patients with 
  -blocker pretreatment in whom this therapy is contin-
ued after admission do at least as good (or even better) 
than patients without pretreatment, in whom   -blockers 
are started after admission. In 1,045 of 7,684 patients 
(13.6%) with previous   -blockers, this therapy was 
stopped after admission. Despite the fact that we do not 
know the exact reasons why clinicians stopped   -block-
ers, we can assume that this was for hemodynamic rea-
sons.
 The latest large prospective trial analyzing the role of 
  -blockers in AMI found that they reduce the risk of re-
infarction and ventricular fibrillation but increase the 
risk of cardiogenic shock, especially during the first day 
after admission  [17] .
 When cautiously interpreted, our data call for a tai-
lored approach. Patients who are pretreated with   -block-
ers and who present with ACS should further receive 
their   -blocker if they are hemodynamically stable since 
this medication has the potential to decrease their MACE 
rate to as much as 41%. Patients without   -blocker pre-
treatment who are hemodynamically stable should re-
ceive this therapy soon after presentation for ACS.
 In our study, patients who never received a   -blocker 
therapy had very high rates of MACE. This is explained 
by their comorbidities (age, diabetes, prevalence of known 
CAD, lower use of aspirin and clopidogrel) but might also 
be related to the fact that they never received   -blockers 
(a proven beneficial therapy for ACS).
Table 5. Multivariate logistic regression for MACE
OR 95% CI p
Previous and continued
-blocker therapy 0.59 0.47–0.74 <0.001
-Blocker therapy at 
admission 0.66 0.55–0.83 <0.001
Age (per year) 1.04 1.04–1.05 <0.001
Gender 1.16 0.97–1.39 0.112
STEMI 1.55 1.30–1.86 <0.001
Killip
II 1.67 1.35–2.07 <0.001
III 2.50 1.82–3.44 <0.001
IV 15.6 11.3–21.7 <0.001
Hypertension 0.84 0.70–1.01 0.069
Dyslipidemia 0.79 0.67–0.94 0.009
Smoking 1.22 1.00–1.50 0.055
Charlson score 1 1.42 1.13–1.79 0.003
Charlson score 2 1.72 1.32–2.24 <0.001
Charlson score ≥3 2.21 1.73–2.83 <0.001
Primary PCI 0.59 0.49–0.72 <0.001
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 Limitations 
 We are aware that these are registry data, which should 
be interpreted with caution. Since the baseline character-
istics of the different   -blocker groups were so different, 
a comparison of the outcomes is difficult and remains 
challenging despite the use of multivariate logistic re-
gression.
 Additionally, we cannot provide data which types of 
  -blockers and in which dose they were used. Global data 
about baseline ejection fraction are not available for most 
of the patients and this limits the interpretations of the 
data since ejection fraction affects patient’s response to 
treatment with   -blockers.
 Conclusions 
 This study confirms the potential benefit of   -block-
ers in patients with ACS.   -Blockers have the potential to 
markedly reduce in-hospital mortality and MACE rates 
in ACS patients. Hemodynamically stable patients with-
out   -blocker pretreatment should receive them upon ad-
mission, and this therapy should be continued in those 
already on   -blockers.
 Appendix 
 AMIS Plus Participants 1997–2007 
 The following hospitals participated from 1997–2007 in the 
AMIS registry on which this report is based (in alphabetical or-
der): Affoltern am Albis, Bezirkspital (F. Hess), Altdorf, Kantons-
spital (R. Simon), Altstätten, Kantonales Spital (P.J. Hangartner/
M. Rhyner), Aarau, Kantonsspital (P. Lessing), Baden, Kantons-
spital (M. Neuhaus/U. Hufschmid), Basel, Kantonsspital (P. Hun-
ziker), Basel, St. Claraspital (C. Grädel), Bern, Beau-Site Klinik 
(A. Schönfelder), Bern, Inselspital (B. Meier/S. Windecker), Biel, 
Spi talzentrum (H. Schläpfer), Brig-Glis, Oberwalliser Kreisspital 
(D. Evéquoz), Bülach, Spital (R. Pampaluchi/A. Ciurea-Löchel/M. 
Kruhl/A. Vögele), Burgdorf, Regionalspital Emmental (D. Ryser), 
Chur, Rätisches Kantons- und Regionalspital (P. Müller), Chur, 
Kreuzspital (V. Wüscher/R. Jecker), Davos, Spital (G. Niedermai-
er), Dornach, Spital (A. Koelz/H. Lederer), Flawil, Kantonales 
Spital (T. Langenegger/J. Haarer), Frauenfeld, Kantonsspital
(H.P. Schmid), Fribourg, Hôpital cantonal (B. Quartenoud), 
Frutigen, Spital (S. Moser/K. Bietenhard), Genève, Hôpitaux uni-
versitaires (HUG) (J.M. Gaspoz/P.F. Keller), Glarus, Kantonsspi-
tal (W. Wojtyna), Grenchen, Spital (P. Schlup/A. Oestmann/B. 
Oertli/R. Schönenberger), Grosshöchstetten, Bezirksspital (C. Si-
monin), Heiden, Kantonales Spital (R. Waldburger), Herisau, 
Kantonales Spital (P. Staub/M. Schmidli), Interlaken, Spital (P. 
Sula/E.M. Weiss), Jegenstorf, Spital (H. Marty), La Chaux-de-
Fonds, Hôpital (H. Zender), Lachen, Regionalsspital (I. Poepping/
C. Steffen), Langnau im Emmental, Regionalspital (J. Sollberger/
A. Hugi), Laufenburg, Gesundheitszentrum Fricktal (E. Koltai), 
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